Bellerophon Therapeutics (NASDAQ: BLPH) and bluebird bio (NASDAQ:BLUE) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.
This is a breakdown of recent ratings and target prices for Bellerophon Therapeutics and bluebird bio, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings and Valuation
This table compares Bellerophon Therapeutics and bluebird bio’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Bellerophon Therapeutics||N/A||N/A||-$23.81 million||($1.30)||-1.42|
|bluebird bio||$35.43 million||327.20||-$335.64 million||($5.38)||-43.11|
Bellerophon Therapeutics has higher earnings, but lower revenue than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Bellerophon Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
59.9% of Bellerophon Therapeutics shares are held by institutional investors. 60.4% of Bellerophon Therapeutics shares are held by company insiders. Comparatively, 3.9% of bluebird bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
Bellerophon Therapeutics has a beta of -0.32, indicating that its stock price is 132% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500.
This table compares Bellerophon Therapeutics and bluebird bio’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Bellerophon Therapeutics beats bluebird bio on 8 of the 13 factors compared between the two stocks.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company’s second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company’s BCM is in PRESERVATION I clinical trial.
About bluebird bio
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.